Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

A Telemedicine-Based Registration System for the Management of Renal Anemia in Patients on Maintenance Hemodialysis: Multicenter Study.

Ni Z, Jin H, Jiang G, Wang N, Peng A, Guo Z, Bai S, Zhou R, Lu J, Wang Y, Li Y, Zhuang S, Yu C, Deng Y, Jin H, Xu X, Zhang J, Zhao J, Yu X, Wang X, Zhang L, Niu J, Liu K, Bao X, Wang Q, Ma J, Hu C, Zang X, Yu Q.

J Med Internet Res. 2019 May 8;21(5):e13168. doi: 10.2196/13168.

2.

2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.

Tsubakihara Y, Nishi S, Akiba T, Hirakata H, Iseki K, Kubota M, Kuriyama S, Komatsu Y, Suzuki M, Nakai S, Hattori M, Babazono T, Hiramatsu M, Yamamoto H, Bessho M, Akizawa T.

Ther Apher Dial. 2010 Jun;14(3):240-75. doi: 10.1111/j.1744-9987.2010.00836.x.

PMID:
20609178
3.

Effect of facility-level hemoglobin concentration on dialysis patient risk of transfusion.

Collins AJ, Monda KL, Molony JT, Li S, Gilbertson DT, Bradbury BD.

Am J Kidney Dis. 2014 Jun;63(6):997-1006. doi: 10.1053/j.ajkd.2013.10.052. Epub 2013 Dec 4.

PMID:
24315770
4.

Anemia management trends in hospital-based dialysis centers (HBDCs), 2010 to 2013.

Coritsidis GN, Maglinte GA, Acharya A, Saxena A, Chang CL, Hill J, Gitlin M, Lafayette RA.

Clin Ther. 2014 Mar 1;36(3):408-18. doi: 10.1016/j.clinthera.2014.01.015. Epub 2014 Feb 28.

PMID:
24582713
5.

Prevalence and management of anemia in hemodialysis patients in a Brazilian population of predominantly African descent.

Matos CM, Silva LF, D'Ávila Melo NA, Kuwano AY, Kuwano AN, Azul PS, Barros LL, Pisoni RL, Lopes AA.

Int J Artif Organs. 2013 Oct 3;36(9):640-9. doi: 10.5301/ijao.5000204. Epub 2013 May 20.

PMID:
23918268
6.

Anemia Evaluation and Erythropoietin Dose Requirement Among Hemodialysis Patients: a Multicenter Study.

Nafar M, Samavat S, Khoshdel A, Alipour-Abedi B.

Iran J Kidney Dis. 2017 Jan;11(1):56-65.

7.

Anemia and hypoalbuminemia at initiation of hemodialysis as risk factor for survival of dialysis patients.

Anees M, Ibrahim M.

J Coll Physicians Surg Pak. 2009 Dec;19(12):776-80. doi: 12.2009/JCPSP.776780.

PMID:
20042156
8.

Effect of frequency of intravenous iron administration on hemoglobin variability in maintenance hemodialysis patients.

Wan L, Zhang D.

Int Urol Nephrol. 2018 Aug;50(8):1511-1518. doi: 10.1007/s11255-018-1916-8. Epub 2018 Jun 26.

PMID:
29946818
9.

[Opatija study: observation of hemodialysis patients and titration of CERA dose just switched from another erythropoiesis stimulating agent].

Jelić I, Lovcić V, Kurtović I, Josipović M, Havranek Z, Kostić L, Racki S.

Acta Med Croatica. 2012 Jul;66(3):157-64. Croatian.

PMID:
23441529
10.

Efficacy and Long-Term Safety of C.E.R.A. Maintenance in Pediatric Hemodialysis Patients with Anemia of CKD.

Fischbach M, Wühl E, Reigner SCM, Morgan Z, Schaefer F.

Clin J Am Soc Nephrol. 2018 Jan 6;13(1):81-90. doi: 10.2215/CJN.03570417. Epub 2017 Nov 2. Erratum in: Clin J Am Soc Nephrol. 2019 Jun 7;14(6):907.

11.

Current management of anemia in adult hemodialysis patients with end-stage renal disease.

Frankenfield DL, Johnson CA.

Am J Health Syst Pharm. 2002 Mar 1;59(5):429-35.

PMID:
11887409
12.

An open-label, sequential, dose-finding study of peginesatide for the maintenance treatment of anemia in chronic hemodialysis patients.

Besarab A, Zeig SN, Martin ER, Pergola PE, Whittier FC, Zabaneh RI, Schiller B, Mayo M, Francisco CA, Polu KR, Duliege AM.

BMC Nephrol. 2012 Aug 30;13:95. doi: 10.1186/1471-2369-13-95.

13.

Hemoglobin variability in epoetin-treated hemodialysis patients.

Berns JS, Elzein H, Lynn RI, Fishbane S, Meisels IS, Deoreo PB.

Kidney Int. 2003 Oct;64(4):1514-21.

14.

Safety and Efficacy of PDpoetin for Management of Anemia in Patients with end Stage Renal Disease on Maintenance Hemodialysis: Results from a Phase IV Clinical Trial.

Javidan AN, Shahbazian H, Emami A, Yekaninejad MS, Emami-Razavi H, Farhadkhani M, Ahmadzadeh A, Gorjipour F.

Hematol Rep. 2014 Sep 10;6(3):5195. doi: 10.4081/hr.2014.5195. eCollection 2014 Aug 26.

15.

Renal anemia: comparing current Eastern and Western European management practice (ORAMA).

Wiecek A, Covic A, Locatelli F, Macdougall IC; ORAMA study group.

Ren Fail. 2008;30(3):267-76. doi: 10.1080/08860220701857241.

PMID:
18350446
16.
17.

Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study.

Provenzano R, Besarab A, Wright S, Dua S, Zeig S, Nguyen P, Poole L, Saikali KG, Saha G, Hemmerich S, Szczech L, Yu KH, Neff TB.

Am J Kidney Dis. 2016 Jun;67(6):912-24. doi: 10.1053/j.ajkd.2015.12.020. Epub 2016 Feb 2.

18.

Adverse events in chronic hemodialysis patients receiving intravenous iron dextran--a comparison of two products.

McCarthy JT, Regnier CE, Loebertmann CL, Bergstralh EJ.

Am J Nephrol. 2000 Nov-Dec;20(6):455-62.

PMID:
11146312
19.

Low levels of serum ferritin and moderate transferrin saturation lead to adequate hemoglobin levels in hemodialysis patients, retrospective observational study.

Ogawa C, Tsuchiya K, Tomosugi N, Kanda F, Maeda K, Maeda T.

PLoS One. 2017 Jun 29;12(6):e0179608. doi: 10.1371/journal.pone.0179608. eCollection 2017.

20.

Hemoglobin levels and erythropoietin doses in hemodialysis and peritoneal dialysis patients in the United States.

Snyder JJ, Foley RN, Gilbertson DT, Vonesh EF, Collins AJ.

J Am Soc Nephrol. 2004 Jan;15(1):174-9.

Supplemental Content

Support Center